WHO ICTRP trial
Open-label Study of ELA026 in Participants with sHLH (short title)
CTIS2025-520624-25-00 · EU Clinical Trials Information System · Recruiting
Key facts
| Trial ID | CTIS2025-520624-25-00 |
|---|---|
| Public title | Open-label Study of ELA026 in Participants with sHLH (short title) |
| Scientific title | A Phase 2/3, Open-label, Single-arm, Multicenter, Historical Control Study to Evaluate ELA026 in Participants with Secondary Hemophagocytic Lymphohistiocytosis (sHLH) - ELA026-CP002 |
| Primary sponsor | Electra Therapeutics Inc. |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): Yes Therapeutic confirmatory - (Phase III): Yes Therapeutic use - (Phase IV): No |
| Countries | United States;United Kingdom;Israel;Germany;Spain;Netherlands;Italy |
| Conditions | Secondary Hemophagocytic Lymphohistiocytosis (sHLH) MedDRA version: 20.0Level: SOCClassification code: 10021428Term: Immune system disorders Class: 4;Therapeutic area: Diseases [C] - Immune System Diseases [C20] |
| Interventions | Product Name: ELA026, Product Code:PRD11289609, Pharmaceutical Form: INFUSION, Other descriptive name: , Strength: |
| Registration date | Sep 4, 2025 |
| Target size | 100 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: